Vertigo and motion sickness. Part II: pharmacologic treatment

Ear, Nose & Throat Journal, Jan, 2006 by Timothy P. Zajonc, Peter S. Roland

(52.) Lassen LF, Hirsch BE, Kamerer DB. Use of nimodipine in the medical treatment of Meniere's disease: Clinical experience. Am J Otol 1996;17:577-80.

(53.) Marley JE, Joy MD. Alleviation of motion sickness by nifedipine [letter]. Lancet 1987;2:1265.

(54.) Takeda N, Morita M, Yamatodani A, et al. Catecholaminergic responses to rotational stress in rat brain stem: Implications for amphetamine therapy of motion sickness. Aviat Space Environ Med 1990;61:1018-21.

(55.) Kohl RL, Lewis MR. Mechanisms underlying the antimotion sickness effects of psychostimulants. Aviat Space Environ Med 1987;58:1215-18.

(56.) Kohl RL, Calkins DS, Mandell AJ. Arousal and stability: The effects of five new sympathomimetic drugs suggest a new principle for the prevention of space motion sickness. Aviat Space Environ Med 1986;57:137-43.

(57.) McMillan BA. CNS stimulants: Two distinct mechanisms of action for amphetamine-like drugs. Trends Pharmacol Sci 1983;4: 429-32.

(58.) Kohl RL, Sandoz GR, Reschke MF, et al. Facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine. J Clin Pharmacol 1993;33:1092-1103.

(59.) Freeman AJ, Bountra C, Dale TJ, et al. The vomiting reflex and the role of 5-HT3 receptors. Anticancer Drugs 1993;4(suppl 2):9-15.

(60.) Yates BJ, MillerAD, Lucot JB. Physiological basis and pharmacology of motion sickness: An update. Brain Res Bull 1998;47:395-406.

(61.) Lucot JB, Crampton GH. Buspirone blocks motion sickness and xylazine-induced emesis in the cat. Aviat Space Environ Med 1987;58:989-91.

(62.) Lucot JB. Effects of serotonin antagonists on motion sickness and its suppression by 8-OH-DPAT in cats. Pharmacol Biochem Behav 1990;37:283-7.

(63.) Lucot JB. Antiemetic effects of flesinoxan in cats: Comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin. Eur J Pharmacol 1994;253:53-60.

(64.) Biver F, Goldman S, Luxen A, et al. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. Eur J Nucl Med 1994;21: 937-46.

(65.) Okada F, Salto H, Matsuki N. Blockade of motion- and cisplatin-induced emesis by a 5-HT2 receptor agonist in Suncus murinus. Br J Pharmacol 1995;114:931-4.

(66.) Okada F, Salto H, Matsuki N. Prophylactic effect of serotonin uptake inhibitors against motion sickness in Suncus murinus. Eur J Pharmacol 1996;309:33-5.

(67.) Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996;52:773-94.

(68.) Stott JR, Barnes GR, Wright RJ, Ruddock CJ. The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties. Br J Clin Pharmacol 1989;27:147-57.

(69.) Gardner CJ, Twissell DJ, Dale TJ, et al. The broad-spectrum antiemetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol 1995;116:3158-63.

(70.) Beattie DT, Beresford IJ, Connor HE, et al. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist. Br J Pharmacol 1995;116:3149-57.